| Patents for A61P 7 - Drugs for disorders of the blood or the extracellular fluid (67,065) |
|---|
| 06/13/2002 | WO2002046383A2 Protein modification and maintenance molecules |
| 06/13/2002 | WO2002046373A1 Method of collecting placental stem cells |
| 06/13/2002 | WO2002046213A2 Methods and reagents for isolating angiogenic modulators |
| 06/13/2002 | WO2002046197A1 Macroheterocylic compounds useful as kinase inhibitors |
| 06/13/2002 | WO2002046193A2 Heterocyclic ether substituted imidazoquinolines |
| 06/13/2002 | WO2002046192A2 Thioether substituted imidazoquinolines |
| 06/13/2002 | WO2002046191A2 Urea substituted imidazoquinoline ethers |
| 06/13/2002 | WO2002046190A2 Sulfonamido ether substituted imidazoquinolines |
| 06/13/2002 | WO2002046189A2 Aryl ether substituted imidazoquinolines |
| 06/13/2002 | WO2002046188A2 Amido ether substituted imidazoquinolines |
| 06/13/2002 | WO2002046184A1 Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases |
| 06/13/2002 | WO2002046170A2 Anilinopyrimidine derivatives as jnk pathway inhibitors and compositions and methods related thereto |
| 06/13/2002 | WO2002046169A1 Substituted 2-anilino-benzimidazoles and the use thereof as nhe-inhibitors |
| 06/13/2002 | WO2002046160A2 Process for making a thrombin inhibitor |
| 06/13/2002 | WO2002046159A1 Guanidine and amidine derivatives as factor xa inhibitors |
| 06/13/2002 | WO2002046147A2 Perturbed membrane-binding compounds |
| 06/13/2002 | WO2002046138A2 Synthesis, methods of using, and compositions of hydroxylated cyclobutylalkylamines |
| 06/13/2002 | WO2002045652A2 Tyrosine kinase inhibitors |
| 06/13/2002 | WO2002028825A3 Aminopyridinyl-, aminoguanidinyl- and alkoxyguanidinyl- substituted phenyl acetamides as protease inhibitors |
| 06/13/2002 | WO2002012245A3 Azabicyclic derivatives and their therapeutic use |
| 06/13/2002 | WO2002008219A3 2-adamantylethylamines and their use in the treatment of conditions generally associated with abnormalities in glutamatergic transmission |
| 06/13/2002 | WO2001096879A3 Method and apparatus for monitoring anti-platelet agents |
| 06/13/2002 | WO2001096330A3 Thrombin receptor antagonists |
| 06/13/2002 | WO2001094415A3 Nuclear hormone receptor |
| 06/13/2002 | WO2001091775A3 Preparation of a pathogen inactivated solution of red blood cells having reduced immunogenicity |
| 06/13/2002 | WO2001090104A3 -(pyrrolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives and their use as modulators of protein kinases |
| 06/13/2002 | WO2001072843A3 Regulation of human c-myb-related genes |
| 06/13/2002 | WO2001059103A3 Method and reagent for the modulation and diagnosis of cd20 and nogo gene expression |
| 06/13/2002 | US20020072631 2-amino-2-alkyl-3 hexenoic and hexynoic acid derivatives useful as nitric oxide synthase inhibitors |
| 06/13/2002 | US20020072630 Therapy |
| 06/13/2002 | US20020072596 Nucleotide sequences coding transrerrins; for use in the treatment of nervous system., blood abbd anemia, heme biosynthesis disorders |
| 06/13/2002 | US20020072539 For therapy of tumor necrosis factor(TNF), edema, neurological deficits, stroke and for therapy of pathological conditions caused by TNF-alpha |
| 06/13/2002 | US20020072534 20- Hete antagonists and agonists |
| 06/13/2002 | US20020072531 Useful as anticoagulants in mammals; inhibitors of factor Xa |
| 06/13/2002 | US20020072530 Indole and benzimidazole inhibitors of factor Xa |
| 06/13/2002 | US20020072515 For therapy and prophylaxis of ischemic heart diseases such as angina pectoris, arrhythmia, myocardial infarction, congestive heart failure, cerebral infarction and cerebral sequelae after subarachnoid hemorrhage, hypertension |
| 06/13/2002 | US20020072509 Methods for the treatment of a traumatic central nervous system injury |
| 06/13/2002 | US20020072090 Hr-1 receptor |
| 06/13/2002 | US20020071822 Polymer comprising a backbone comprising ester, thioester, or amide linkages, and wherein the backbone comprises one or more groups that will yield a biologically active compound upon hydrolysis of the polymer. |
| 06/13/2002 | CA2678490A1 Isolated placental perfusate and placental cells isolated therefrom |
| 06/13/2002 | CA2436984A1 Urea substituted imidazoquinoline ethers |
| 06/13/2002 | CA2436983A1 Sulfonamido ether substituted imidazoquinolines |
| 06/13/2002 | CA2436899A1 Synthesis, methods of using, and compositions of hydroxylated cyclobutylalkylamines |
| 06/13/2002 | CA2436732A1 Protein modification and maintenance molecules |
| 06/13/2002 | CA2436601A1 Perturbed membrane-binding compounds |
| 06/13/2002 | CA2431187A1 Macroheterocylic compounds useful as kinase inhibitors |
| 06/13/2002 | CA2431151A1 Heterocyclic ether substituted imidazoquinolines |
| 06/13/2002 | CA2430989A1 Method of collecting placental stem cells |
| 06/13/2002 | CA2430966A1 Anilinopyrimidine derivatives as jnk pathway inhibitors and compositions and methods related thereto |
| 06/13/2002 | CA2430844A1 Aryl ether substituted imidazoquinolines |
| 06/13/2002 | CA2430842A1 Process for making a thrombin inhibitor |
| 06/13/2002 | CA2430558A1 Proteins and nucleic acids encoding same |
| 06/13/2002 | CA2430412A1 Substituted 2-anilino-benzimidazoles and the use thereof as nhe-inhibitors |
| 06/13/2002 | CA2430206A1 Screening method for identifying compounds that selectively induce interferon alpha |
| 06/13/2002 | CA2429728A1 Tyrosine kinase inhibitors |
| 06/13/2002 | CA2429641A1 Kinases and phosphatases |
| 06/12/2002 | EP1213032A1 Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
| 06/12/2002 | EP1212433A2 Protein phosphatases and diagnosis and treatment of phosphatase-related disorders |
| 06/12/2002 | EP1212421A1 Gas1 polypeptides |
| 06/12/2002 | EP1212407A1 Immunoglobulin superfamily polynucleotides, polypeptides, and antibodies |
| 06/12/2002 | EP1212405A2 Use of cytokines, cells, and mitogens to inhibit graft versus host disease |
| 06/12/2002 | EP1212403A1 Method for treatment of beta-hemoglobinopathies |
| 06/12/2002 | EP1212352A1 Peptide analogs as selective inhibitors of thrombin activation of protease activated receptor 1 |
| 06/12/2002 | EP1212344A1 B7-like polynucleotides, polypeptides, and antibodies |
| 06/12/2002 | EP1212330A1 Androgen receptor modulator compounds and methods |
| 06/12/2002 | EP1212328A1 Compounds, methods and pharmaceutical compositions for treating cellular damage, such as neural or cardiovascular tissue damage |
| 06/12/2002 | EP1212327A2 Pyrazolopyrimidines as therapeutic agents |
| 06/12/2002 | EP1212323A2 Substituted pyridino pentaazamacrocyle complexes having superoxide dismutase activity |
| 06/12/2002 | EP1212322A2 8-substituted-6-trifluoromethyl-9-pyrido[3,2-g]quinoline compounds as androgen receptor modulators |
| 06/12/2002 | EP1212303A2 Bicyclic androgen and progesterone receptor modulator compounds and methods |
| 06/12/2002 | EP1212300A1 Azacycloalkanone serine protease inhibitors |
| 06/12/2002 | EP1212087A1 Methods and compositions utilizing rad51 |
| 06/12/2002 | EP1212059A1 Iron chelators and uses thereof |
| 06/12/2002 | EP0939655B1 Stable protein and nucleic acid formulations using non-aqueous, anhydrous, aprotic, hydrophobic, non-polar vehicles with low reactivity |
| 06/12/2002 | EP0881901B1 New associations of active principles containing clopidogrel and an antithrombotic agent |
| 06/12/2002 | EP0859621B1 Biocompatible aqueous solution for use in continuous ambulatory peritoneal dialysis |
| 06/12/2002 | EP0855913B1 Iron dextran formulations |
| 06/12/2002 | EP0802800B1 Biocompatible immunoisolatory capsules containing genetically altered cells for the delivery of biologically active molecules |
| 06/12/2002 | EP0741576B1 Co-administration of interleukin-3 mutants with colony stimulating factors |
| 06/12/2002 | EP0688211B1 Thalidomide for inhibition of angiogenesis |
| 06/12/2002 | CN1353710A 5-pyridyl-1,3-azole compounds, process for producing the same and use thereof |
| 06/12/2002 | CN1353706A Integrin receptor ligands |
| 06/12/2002 | CN1353705A Pyrazinone thrombin inhibitors |
| 06/12/2002 | CN1353690A Bradykinin receptor antagonists |
| 06/12/2002 | CN1353684A Ether compounds, compositions, and uses thereof |
| 06/12/2002 | CN1353612A Tanacetum parthenium extract |
| 06/12/2002 | CN1353610A Medicinal composition for oral administration |
| 06/12/2002 | CN1353609A Amide substituted imidazoquinolines |
| 06/12/2002 | CN1353606A IL-8 receptor antagonists |
| 06/12/2002 | CN1353003A Process for screening active component from plant extract |
| 06/12/2002 | CN1352945A Adenosine as anti-thrombosis medicine |
| 06/12/2002 | CN1086128C Chinese medicine preparation for preventing and curing cerebral thrombus |
| 06/11/2002 | US6403830 Amidino compound and salts thereof useful as nitric oxide synthase inhibitors |
| 06/11/2002 | US6403758 Bioresorbable compositions for implantable prostheses |
| 06/11/2002 | US6403647 Pulsed administration of compositions for the treatment of blood disorders |
| 06/11/2002 | US6403583 Anticoagulant agents for treatment and prevention of thromboembolic disorders. |
| 06/11/2002 | US6403570 Method of curing an injury to a skin surface |
| 06/11/2002 | US6403567 To stimulate mammalian coronary vasodilatation and for imaging the heart; regadenoson |
| 06/11/2002 | US6403559 C-kit ligand-based method for expanding peripheral blood cell levels |
| 06/11/2002 | US6403556 Pharmaceutical preparation containing protein C and a thrombolytically active substance |